字号·· | 护眼
半岛电视台

每日一片药能否缩小全球南方的糖尿病治疗差距?Could one daily pill narrow the diabetes treatment gap in the Global South?

点「原文对照」整页切到原文,或双击某段只看那段的原文。

对于无法控制糖尿病的患者而言,作为救命稻草的药物正在缓慢地从注射剂转向口服药,这一变化可能从根本上改变该疾病的治疗方式——以及谁能获得治疗。

Medication that has been a lifeline for patients with uncontrollable diabetes is now slowly shifting from injections to pills, a move that could fundamentally alter treatment for the disease – and who can access it.

这一转变也可能影响肥胖症的治疗。肥胖症是一种长期被误解的疾病,过去常被归因于暴饮暴食和懒惰,而非如今公认的代谢紊乱。

This shift could also affect the treatment of obesity, a long misunderstood condition once associated with overeating and laziness, rather than the metabolic disorder it is now recognised as. GLP-1 (glucagon-like peptide-1) receptor agonists therapy isn’t new.

GLP-1(胰高血糖素样肽-1)受体激动剂疗法并非新事物。首个获美国食品药品监督管理局(FDA)批准的药物艾塞那肽于2005年上市,随后利拉鲁肽于2009年获批,被视为胰岛素的革命性替代方案。

The first FDA-approved drug, Exenatide, hit the market in 2005 and was followed by Liraglutide in 2009, which was seen as a revolutionary alternative to insulin. But the market has until recently been dominated by weekly injections like Ozempic and Wegovy (semaglutide), and Mounjaro (tirzepatide).

但直到最近,市场一直由每周注射一次的药物主导,如奥西金和维高(司美格鲁肽),以及莫捷诺(替尔泊肽)。这些药物在减重方面也被证明有效。

These drugs have also proved successful for weight loss. Now, once-daily oral GLP pills are emerging as an alternative, especially for the diabetes-stricken Global South.

如今,每日一次的口服GLP药片正作为一种替代方案浮现,尤其是对深受糖尿病困扰的“全球南方”国家而言。

Oral once-daily pills of the same wonder drug could make access more affordable, and less reliant on the cold chain that GLP-1 injections and insulin depend on – and that are harder to secure in emerging economies.

同样的“神药”若制成每日一次的口服药片,可能使获取更负担得起,并减少对冷链的依赖——GLP-1注射剂和胰岛素都依赖冷链,而在新兴经济体中冷链更难保障。

Why this matters One in nine people in the world between the ages of 20-79 lives with diabetes, and one in eight people globally is obese.

为何这很重要 全球20至79岁人群中,每9人就有1人患有糖尿病;全球每8人中就有1人肥胖。

The GLP injections come with a high price tag and are often not covered by insurance companies, which treat them as an elective drug.

GLP注射剂价格高昂,且往往不被保险公司覆盖,保险公司将其视为非必需药物。

In the United States, Eli Lily’s Mounjaro costs about $500 for a month’s worth of doses; in the UK, about 199 pounds ($264); and in Saudi Arabia, 1,261 riyals ($336).

在美国,礼来公司的莫捷诺一个月剂量约500美元;在英国,约199英镑(约合264美元);在沙特阿拉伯,约1261里亚尔(约合336美元)。在印度,该品牌在当地生产,售价14766卢比(约合157美元)。在巴基斯坦,进口的莫捷诺高达22万卢比(约合723美元),而当地企业Getz Pharma生产的替尔泊肽售价1.7万卢比(约合61美元)。药片通常每日服用一次,而注射剂则每周注射一次。

In India, the brand is locally manufactured and available at 14,766 rupees ($157). In Pakistan, the imported Mounjaro is a whopping 220,000 rupees ($723), while the locally manufactured Tirzepatide from Getz Pharma costs 17,000 rupees ($61). While pills are usually taken once a day, injections are once per week. Pakistan has the highest diabetes prevalence in the world – 31.4 percent of its population suffer from the disease – followed by the Marshall Islands (25.7 percent) and Kuwait (25.6 percent).

巴基斯坦的糖尿病患病率居世界首位,其人口中有 31.4% 患有该病,其次是马绍尔群岛(25.7%)和科威特(25.6%)。许多其他中东国家也位列糖尿病患病率最高的国家之中。巴基斯坦 31.4%。马绍尔群岛 25.7%。科威特 25.6%。萨摩亚 25.4%。卡塔尔 24.6%。基里巴斯 24.6%。沙特阿拉伯 23.1%。法属波利尼西亚 22.8%。埃及 22.4%。巴林 22.1%。

Many other Middle Eastern countries rank among nations with the highest diabetes prevalence. Pakistan 31.4 percent. Marshall Islands 25.7 percent. Kuwait 25.6 percent. Samoa 25.4 percent. Qatar 24.6 percent. Kiribati 24.6 percent. Saudi Arabia 23.1 percent. French Polynesia 22.8 percent. Egypt 22.4 percent. Bahrain 22.1 percent. For many countries in the Global South, the relative affordability of oral GLP drugs, where the locally manufactured oral semaglutide is about $18 for a 30-day supply, could make them more accessible for diabetes and obesity patients, remove the need for refrigeration and make rural distribution easier.

对于许多全球南方国家而言,口服 GLP 类药物的相对可负担性——当地生产的口服司美格鲁肽 30 天用量约为 18 美元——可能使糖尿病和肥胖症患者更容易获得治疗,免除冷藏需求,并让农村地区分发更加便利。

Dr Zakir Alavi is an endocrinologist in Karachi, Pakistan and has been treating patients with diabetes and obesity for nearly 30 years.

扎基尔·阿拉维医生是巴基斯坦卡拉奇的一名内分泌科医生,治疗糖尿病和肥胖症患者已近 30 年。

“Pakistan is a country of contrast. We have, on one hand, childhood malnutrition, underweight, and stunted growth. On the other hand, we have childhood and adult obesity,” said Alavi.

阿拉维说:“巴基斯坦是一个充满反差的国家。一方面,我们面临儿童营养不良、体重不足和发育迟缓;另一方面,又存在儿童和成人肥胖问题。令人惊讶的是,成人和儿童肥胖中至少有一部分因素,可以追溯到母亲营养不良、婴儿低体重早产。”医生指出,孕期营养不良会导致低出生体重,而出生体重低、婴儿期体重迅速增加的婴儿,日后患儿童肥胖症的风险更高。

“And surprisingly, there is at least some element in the adult and childhood obesity which can be linked to a malnourished mother, and an underweight, premature baby.”Malnutrition during pregnancy can lead to low birth weight, and babies born small who gain weight rapidly in infancy face a higher risk of childhood obesity, according to doctors.

一名医护人员在2025年7月,于信德省苏贾瓦尔县法特赫·穆罕默德·苏姆罗村的联合国儿童基金会营养项目中,检查完儿童后分发药物 []阿拉维表示,GLP类药物——无论是注射剂还是药丸——已经彻底改变了2型糖尿病和肥胖症的管理。它们不仅帮助2型糖尿病患者控制体重,还能帮助非糖尿病患者应对肥胖,改善心脏和肾脏结局、肝脏疾病、阻塞性睡眠呼吸暂停和骨关节炎。

A health worker hands out medicine after checking on children during a UNICEF nutrition programme at Fateh Muhammad Soomro village in the Sujawal district of Sindh province in July 2025 [File: Juliette Mansour/AFP] Alavi said GLP drugs – whether the injectables or pills – have revolutionised the management of type 2 diabetes and obesity. They not only help type 2 diabetes patients manage their weight, but can also help non-diabetics tackle obesity, improving cardiac and renal outcomes, liver disease, obstructive sleep apnea and osteoarthritis.

一名卫生工作者在2025年7月,于信德省苏贾瓦尔县法特赫·穆罕默德·苏姆罗村的联合国儿童基金会营养项目中,检查儿童后分发药物。【资料照片:Juliette Mansour/法新社】A health worker hands out medicine after checking on children during a UNICEF nutrition programme at Fateh Muhammad Soomro village in the Sujawal district of Sindh province in July 2025 [File: Juliette Mansour/AFP]

他说:“当减重很重要、控糖很重要,或者两者都很重要时,它们都可用于管理所有这些情况。”

“They can be used for management of all these things when weight reduction is important, or sugar control is important, or both,” he said.

拉亚兹·马利克是威尔康奈尔医学院卡塔尔分校的医学教授,也是多哈哈马德医疗公司的高级顾问。马利克一直在帮助糖尿病和肥胖症患者的第一线,他赞同阿拉维的观点。

Rayaz Malik is a professor of medicine at Weill Cornell Medica College Qatar, and a senior consultant at Hamad Medical Corporation in Doha. Malik has been at the front line of helping patients with diabetes and obesity, and he echoed Alavi’s views.

他说:“我们研究了治愈糖尿病需要减掉多少体重,那个神奇的数字似乎至少在15公斤左右。”他指的是关于该主题的研究。

“We looked at how much weight you need to lose to cure diabetes, the magic number seemed to come in at around 15kg, at least,” he said, speaking of research on the subject.

随着GLP药物口服药丸形式的更广泛供应,治愈糖尿病对更多人来说比以往任何时候都更近了一步。鸣谢:Rayaz Malik GLP疗法是如何被发现的?

With the wider availability of GLP medication in oral pill form, a cure for diabetes is closer than ever for many more people. Courtesy: Rayaz Malik How was GLP therapy discovered?

延斯·尤尔·霍尔斯特是GLP革命背后的核心科学家之一,这场革命让世界各地数百万人有了与糖尿病共存的方式,也让那些与肥胖作斗争的人有了夺回健康身体的机会。

Jens Juul Holst is one of the central scientists behind the GLP revolution that has given millions around the world a way to live with diabetes and, for those struggling with obesity, a chance to reclaim their bodies.

鸣谢:Rayaz MalikCourtesy: Rayaz Malik

作为一名教授、医生和生理学家,霍尔斯特生活在哥本哈根,他在20世纪70年代开始了对肠道激素的研究。

A professor, physician and physiologist, Holst lives in Copenhagen and began his journey with gut hormones in the 1970s.

“当我们发现这一点时,我们发现的是一种来自肠道的促胰岛素释放肽,”霍尔斯特告诉半岛电视台。“我们对调节胰岛素分泌的因素感兴趣,这是一种生理机制,因为我们有一些人出现了血糖过低的情况,即低血糖症,我们在寻找一种能刺激胰岛素释放并导致血糖水平降低的肽。”他说,反应性低血糖——患者在减重手术等某些手术后出现的症状——解释了GLP分子的作用机制。

“When we discovered this, what we found was an insulin-releasing peptide from the gut,” Holst told Al Jazeera. “We were interested in what regulates insulin secretion, and that was as a physiological mechanism because we had some people who were developing too low blood glucose levels, [which is called] hypoglycemia, and we were looking for a peptide that could create insulin release stimulation and then be responsible for the low glucose levels.”He says reactive hypoglycemia, which patients experience after certain operations like bariatric surgery, explains how the GLP molecule works.

最终,他的团队发现,这种分子不仅在胰岛素释放和分泌中发挥作用,还有助于调节食欲和食物摄入。

Eventually, his team discovered that the molecule plays a role not only in insulin release and secretion, but also helps regulate appetite and food intake.

【鸣谢:Jens Juul Holst】[Courtesy: Jens Juul Holst]

“这一发现实际上可能比发现其促胰岛素释放活性更令人兴奋,”霍尔斯特说,声音中透出兴奋。“而真正的大日子是我们能够向糖尿病患者注射这种新肽并观察会发生什么的时候。”

“The discovery of that was actually perhaps even more exciting than the discovery of its insulin-releasing activities,” Holst said, the excitement in his voice rising. “And then, the big day really was when we were able to infuse people with diabetes with this new peptide and see what happened.”

他们发现,静脉注射GLP-1“会在四小时内使长期患有棘手的2型糖尿病患者的血糖水平完全恢复正常,”他说。“从那时起,我们就知道我们真的发现了重大的东西。”霍尔斯特和他的团队的发现促成了现在被称为司美格鲁肽的药物,这为另一种药物替尔泊肽铺平了道路,还有一种名为瑞塔鲁肽的第三种药物目前正在进行试验,有望于2027年上市。

They found that an intravenous infusion of GLP-1 “would normalise blood glucose levels completely in people with long-standing, problematic type 2 diabetes and this happened in the course of four hours,” he said. “From then on, we knew that we were really onto something big.”Holst and his team’s discovery led to what is now known as semaglutide, which paved the way for another drug, tirzepatide, and a third drug called retatrutide that is currently undergoing trials with a potential release in 2027.

礼来公司和诺和诺德这两家主要制造商预计,GLP市场将从每年800亿美元增长到2030年的1350亿美元。仅肥胖症就在2024年导致了全球370万人死亡。

Eli Lilly and Novo Nordisk, two of the primary manufacturers, expect the GLP market to jump from $80bn per year to $135bn by 2030. Obesity alone was responsible for 3.7 million deaths worldwide in 2024.

2025年12月,世界卫生组织发布指南,建议将GLP-1类药物作为肥胖症的长期治疗方案,肥胖症在全球影响超过10亿人。

In December 2025, the World Health Organization issued guidelines recommending GLP-1 medicines as a long-term treatment for obesity, which affects more than 1 billion people globally.

“当我们意识到这是一种非常好的抗糖尿病疗法时,显而易见,数百万人都能从中受益,”霍尔斯特说。

“As we realised that it was a very good anti-diabetic therapy, it was obvious that millions could benefit from this,” Holst said.

“因为现在你拥有一个占全球40%的人口,他们对调节体重感兴趣,关注度将会非常巨大,”他说,指的是世界卫生组织(WHO)2016年的估计,即全球39%的成年人超重。2024年,世卫组织将这一估计修订为45%。

“Because now you have a population which is 40 percent of the globe who would be interested in regulating body weight and the amount of interest would be huge,” he said, referring to the WHO’s 2016 estimate that 39 percent of adults worldwide are overweight. In 2024, WHO revised this estimate to 45 percent.

肥胖症医生兼顾问斯瓦蒂·普拉丹于2026年3月20日在印度孟买的诊所里讲解身体质量指数(BMI)图表 [] GLP类药物如何起效?

Obesity doctor and consultant Swati Pradhan explains a body mass index (BMI) chart at her clinic in Mumbai, India on March 20, 2026 [File: Indranil Mukherjee/AFP] How do GLP drugs work?

肥胖症医生兼顾问Swati Pradhan于2026年3月20日,在印度孟买的诊所内讲解身体质量指数(BMI)图表。【资料照片:Indranil Mukherjee/法新社】Obesity doctor and consultant Swati Pradhan explains a body mass index (BMI) chart at her clinic in Mumbai, India on March 20, 2026 [File: Indranil Mukherjee/AFP]

注射用GLP药物,特别是替尔泊肽和司美格鲁肽,仍然是最有效的治疗手段,因为它们提供了长期减重和心血管获益的最有力证据。

Injectable GLP medicines, particularly tirzepatide and semaglutide, remain the most effective treatments because they provide the strongest evidence for long-term weight loss and cardiovascular benefits.

人体肠道在进食时会释放一种名为GLP-1的激素。随着血糖升高,GLP-1指示胰腺释放胰岛素。GIP也是一种在进食时释放的肠道激素。与GLP-1一样,它也会在血糖升高时告诉胰腺释放胰岛素。

The human gut releases a hormone called GLP-1 when we eat. As blood sugar rises, GLP-1 instructs your pancreas to release insulin. GIP is a gut hormone also released when we eat. Like GLP-1, it tells the pancreas to release insulin as blood sugar rises.

GLP-1还会减缓食物离开胃部的速度,帮助产生饱腹感。因此,GLP-1类药物模拟该激素的作用,以降低血糖并抑制食欲。

GLP-1 also slows how quickly food leaves your stomach, helping you feel full. GLP-1 medicines, therefore, mimic the hormone’s effects to lower blood sugar and reduce appetite.

想象一个六向路口,红绿灯失灵,导致谁能通行、谁不能通行一片混乱。

Imagine a six-way traffic light when the lights aren’t working, leading to chaos over who can pass the intersection and who can’t.

司美格鲁肽是一种GLP-1药物,作用于单一受体。这就像在这个路口只有一条单行地下通道,意味着车流虽有保证但通行能力有限。

Semaglutide, a GLP-1 drug, works on one receptor. This is like having a single-lane underpass at this intersection, meaning there is a guaranteed flow of traffic, albeit limited.

替尔泊肽兼具GLP和GIP双重作用,即作用于两个受体。这就像拥有一座无信号控制的立交桥、路口红绿灯和一条地下通道,让交通畅通无阻。实际上,器官和细胞被重新引导,按其本应有的方式运作。口服GLP药物的效果能与注射剂媲美吗?

Tirzepatide is a GLP and a GIP, meaning it works on two receptors. That’s like having a signal-free overhead bridge, traffic lights at the intersection and an underpass making traffic much smoother. In effect, the organs and cells are rerouted to work the way they are supposed to. Will oral GLP drugs work as well as the injections?

口服GLP-1类药物承诺提供药片般的便利性,且不会大幅牺牲减重效果,但它们仍面临一个主要障碍:胃部。

Oral GLP-1 medicines promise the convenience of a pill without sacrificing much of the weight-loss effect, but they still face one major hurdle: the stomach.

与将药物直接输送进体内的注射剂不同,口服司美格鲁肽必须在消化过程中存活下来,随后仅有极小部分被吸收。这就是为什么它必须空腹服用,且剂量较高的原因。

Unlike injections, which deliver the drug directly into the body, oral semaglutide must survive digestion before a small fraction is absorbed. That is why it must be taken on an empty stomach and at a higher dose.

然而,较新的口服GLP-1类药物(如奥弗格鲁肽)旨在克服这些限制,可无需空腹服用。

Newer oral GLP-1 drugs such as orforglipron, however, are designed to overcome those limits and can be taken without fasting.

专家表示,虽然口服药物似乎能为许多患者带来与注射剂相似的疗效,但目前仍鲜有直接对比药片与注射剂的头对头临床试验。

While oral drugs appear capable of delivering similar results for many patients, there are still few head-to-head trials comparing pills directly with injections, experts say.

2025年2月11日,在班达亚齐的一处综合服务站,一名男子在接受高血压、胆固醇和糖尿病医疗检查时采集血样。 谁将获益最大?

A man gets his blood sample taken during a medical check-up for hypertension, cholesterol and diabetes at an integrated services post in Banda Aceh on February 11, 2025 [Chaideer Mahyuddin/AFP] Who stands to benefit most? The biggest winners may be people in countries already carrying the world’s heaviest diabetes burden.

一名男子于2025年2月11日,在班达亚齐的一处综合服务站接受医疗检查,抽取血样以检测高血压、胆固醇和糖尿病。【Chaideer Mahyuddin/法新社】A man gets his blood sample taken during a medical check-up for hypertension, cholesterol and diabetes at an integrated services post in Banda Aceh on February 11, 2025 [Chaideer Mahyuddin/AFP]

最大的受益者可能是那些已经承担全球最沉重糖尿病负担的国家的人群。

If future versions become available as tablets and prices fall after patent expiry, the impact in South Asia and the Middle East could be enormous.

马利克表示,如果未来的版本能以片剂形式上市,且专利到期后价格下降,其在南亚和中东的影响可能是巨大的。马利克说,每周一次的口服GLP类药物成为现实已不远。

Malik said once-a-week GLP oral medication isn’t that far from being a reality. Meanwhile, he added, efforts are also under way to develop formulations of the current drugs that are much longer-acting – once-a-month doses might work.

他补充道,与此同时,研发目前药物的长效制剂的工作也在进行中——每月一次给药或许可行。

What makes the GLP-1 drugs work is their ability to mimic what the body naturally does, Malik said.

马利克表示,GLP-1类药物之所以有效,是因为它们能模仿人体自然的生理机制。

“The clever way for treatment is to do what your human body is doing,” he said.

他说:“治疗的聪明做法是顺应人体自身的运作方式。这正在改变人们的生活。”

“And it’s transforming people’s lives.”

阅读媒体原文 ↗